Decellularized tissue matrix in 2026: overview
Decellularized tissue matrix (dECM) is tissue-derived extracellular material processed to remove cells while retaining parts of the native matrix structure and its biochemical cues. Those tissue-specific signals can guide cell behavior in ways synthetic scaffolds may not, while dECM can be formed into sheets, hydrogels, particles or bioinks. The engineering challenge is to remove immunogenic cellular material without damaging the matrix or compromising mechanical behavior, sterility and reproducibility.
Recent work is pushing dECM from passive scaffold toward programmable biofabrication. In September 2026, Nankai University reported woven dECM yarn scaffolds for volumetric muscle-loss repair using immunomodulation; Indian Institute of Technology Hyderabad described osmotic decellularization for lung-matrix bioinks and printed pulmonary constructs. In August 2026, BioGipuzkoa Health Research Institute and the University of the Basque Country compared proteins retained in dECM and dECM inks, highlighting a scale-up issue: processing changes composition. These directions meet at a bottleneck—balancing tissue-specific biology with printability, mechanics and batch consistency.
- 1From matrix to material: Woven dECM yarns and printable lung-matrix bioinks show how researchers are reshaping native tissue material to improve structural control and fabrication.
- 2Preserving the signal: Comparisons of dECM and bioink composition make process-related changes to retained proteins a central concern for reproducibility.
- 3More than grafts: dECM is expanding from repair scaffolds into organoid culture and tissue-specific laboratory models, where native biochemical cues can help shape cell behavior.
Top organizations working on decellularized tissue matrix
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to decellularized tissue matrix. Showing 7 of 1,495 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
University of Sichuan
Research · China |
Physical processing | PAT 2 · PUB 75 | +26% | Recently, its researchers developed a whole-ovary decellularization technique that combines physical preconditioning, including freeze–thaw cycles, to create ovarian bioscaffolds. Work also examines fibrocartilage scaffolds and tissue-specific dECM hydrogels. |
| 2 | 
Tehran University of Medical Sciences
Research · Iran |
General | PUB 45 | -39% | Recently, its researchers developed a 3D culture platform combining decellularized testicular matrix, methylcellulose, and Sertoli cells to support in-vitro spermatogenesis. Other work compares dECM and collagen fabrication for bladder tissue engineering. |
| 3 | 
Sun Yat Sen University
Research · China |
General | PUB 47 | +47% | Recently, its researchers reviewed the use of decellularized extracellular matrix for gastrointestinal organoid culture. Their work also explores decellularized tendon as a structured matrix for tissue regeneration. |
| 4 | 
Pohang University of Science and Technology
Research · South Korea |
General | PAT 1 · PUB 23 NEWS 7 |
+7% | Recently, its researchers developed a nanofiber-supported decellularized matrix membrane to provide a biomimetic niche for intestinal organoid epithelium. Other work uses airway-mucosa-derived matrix bioink for 3D-printed airway tissue. |
| 5 | 
Southern Medical University
Research · China |
General | PUB 61 | +3% | Researchers at the university use decellularized matrices in regenerative scaffolds, including gingiva-derived dECM hydrogels to support osteogenic and angiogenic cell phenotypes and dental-pulp-derived matrix for spinal cord repair. |
| 6 | 
Dalian University of Technology
Research · China |
Detergent-based processing | PUB 20 | -18% | Researchers at the university have combined sodium dodecyl sulfate-based decellularization with 3D bioprinting to make a hydrogel cardiac patch. Other work combines dECM with curcumin for islet-cell therapy and develops hybrid vascular scaffolds. |
| 7 | 
University of Sao Paulo
Research · Brazil |
General | PUB 39 | -23% | Recently, its researchers assessed porcine acellular dermal matrix for root coverage in a clinical case study. They also develop bovine dECM hydrogels for biofabricating female reproductive tissues. |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 16 total
Baiya Phytopharm Co.The company is associated with research combining decellularized matrix, hyaluronic acid, and alginate into hybrid hydrogels for a multilayer oral mucosa-on-a-chip model.- IPImagine PharmaUnited StatesRecently, its researchers reported scalable 3D bioprinting of human islets in pancreatic dECM-enriched bioink for beta-cell replacement research.
Mimetas B.VNetherlandsThe company develops human 3D disease models and is associated with a melanoma-on-a-chip model built using decellularized dermis matrix and integrated vascular and lymphatic networks for drug testing.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 1,299 total
- University of SichuanChinaRecently, its researchers developed a whole-ovary decellularization technique that combines physical preconditioning, including freeze–thaw cycles, to create ovarian bioscaffolds. Work also examines fibrocartilage scaffolds and tissue-specific dECM hydrogels.
- Tehran University of Medical SciencesIranRecently, its researchers developed a 3D culture platform combining decellularized testicular matrix, methylcellulose, and Sertoli cells to support in-vitro spermatogenesis. Other work compares dECM and collagen fabrication for bladder tissue engineering.
- Sun Yat Sen UniversityChinaRecently, its researchers reviewed the use of decellularized extracellular matrix for gastrointestinal organoid culture. Their work also explores decellularized tendon as a structured matrix for tissue regeneration.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where decellularized tissue matrix innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 1,495 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Detergent-based processing | Detergents remove cells from tissue effectively, but can also strip matrix components or leave residues that affect cell compatibility. | 245 |
Tehran University of Medical Sciences, Manipal Academy of Higher Education, University of Sydney |
| Enzymatic processing | Enzymes target cellular material and can preserve matrix structure, but incomplete digestion or residual enzymes can complicate quality control. | 115 |
Tehran University of Medical Sciences, T&R Biofab Co., University of Technology, Sydney |
| Physical processing | Physical methods such as freeze–thaw cycles can support cell disruption without relying solely on chemicals, but may damage tissue structure or leave cellular material behind. | 59 |
Northeast Agricultural University, Canakkale Onsekiz Mart University, Federal University of Ceará |
| Perfusion processing | Perfusion distributes processing agents through vascularized tissue, but depends on accessible vessels and organ-specific process control. | 31 |
Tehran University of Medical Sciences, University of science, Cho Ray Hospital |
| Non-detergent chemical processing | Non-detergent chemicals offer alternatives to detergent-based protocols, but residual reagents and effects on matrix components require careful control. | 33 |
University of Sichuan, Huaqiao University, Arizona Board Of Regents On Behalf Of Arizona State University |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
FACTS records $8,640,179 in grants across 21 awards since 2020, alongside 22 funding rounds totaling $2,227,770,228. The round total may include broad institutional or company financing rather than dECM-specific investment, so treat it cautiously.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Sep 2026Once, I found myself thinking about a question that probably sounds a little strange: what would happen if one of my organs suddenly stopped working? What if my kidneys failed? What if I needed a transplant but there…Science on Medium
- Aug 2026Elutia Inc. (ELUT), a drug-eluting biomatrix company, has completed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for total consideration of up to $11 million, including $8…RTT - Biotech
- Aug 2026Abstract Traumatic brain injury (TBI) remains a major unmet clinical challenge owing to its complex pathophysiology, profound heterogeneity, and limited regenerative capacity of the adult central nervous system (CNS).…Frontiers in Neuroscience | New and Recent Articles
- Jun 2026Abstract Introduction: Peripheral nerve injury (PNI) is characterized by limited regenerative capacity and incomplete functional recovery. Schwann cells (SCs) are essential for nerve repair, but their clinical…Frontiers in Neuroscience | New and Recent Articles
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about decellularized tissue matrix
What companies are working on decellularized tissue matrix?
Patent-active companies include LifeCell, Musculoskeletal Transplant Foundation, T&R Biofab Co. and Rochal Technologies LLC. FACTS also lists CGbio Co.Ltd, AlloSource and Miromatrix Medical Inc. among patent holders. These names indicate activity linked to dECM patents, but do not establish that every organization currently supplies commercial products.
Which decellularized tissue matrix startups are the most promising in 2026?
The startup list includes 16 organizations; Imagine Pharma, Mimetas B.V and Baiya Phytopharm Co. are linked to specific dECM work. Imagine Pharma is associated with 3D bioprinting human islets in pancreatic dECM-enriched bioink, while Mimetas is linked to a decellularized-dermis melanoma-on-a-chip model. These examples show research directions, not a verified ranking of commercial prospects.
Which universities and research centers lead decellularized tissue matrix research?
University of Sichuan leads the listed research organizations with 77 documents in the window; Sun Yat Sen University has 47, and Tehran University of Medical Sciences has 45. Other active groups include Pohang University of Science and Technology and Southern Medical University. Their work spans ovarian bioscaffolds, organoid culture, tissue-specific membranes and regenerative hydrogels.
How much funding has decellularized tissue matrix received?
FACTS lists $8,640,179 in grants across 21 awards since 2020, and 22 funding rounds totaling $2,227,770,228. The round figure should not be read as dECM-specific funding: listed financing includes broad company and institutional activity. The grant total is the clearer indicator of recorded research support, although it does not establish that every award exclusively funds dECM.
Who holds the most decellularized tissue matrix patents?
LifeCell leads the listed patent holders with 14 patents, followed by Musculoskeletal Transplant Foundation with 11 and T&R Biofab Co. with 7. Rochal Technologies LLC has 6, while Yale University and CGbio Co.Ltd each have 5. These counts identify prominent holders in the available patent data, not the full scope or commercial value of each portfolio.
Is decellularized tissue matrix patent activity growing?
Patent activity is down 52.2% in the last 12 months compared with the previous 12 months, with 232 patents recorded in the 24-month window. Publication activity changed less sharply: publications last year were down 2.6%. The contrast suggests that recent work remains research-heavy even as patenting has eased.
How mature is decellularized tissue matrix?
The field includes 125 clinical trials in the recorded data, alongside a large body of research and patent activity. Acellular dermal matrices show that some tissue-derived products have reached clinical use, while newer directions such as organoid culture, printed constructs and tissue-specific hydrogels remain at different stages of development. Clinical translation depends on consistent processing, material characterization and performance.
What are the latest developments in decellularized tissue matrix?
In September 2026, Nankai University reported woven dECM yarn scaffolds for volumetric muscle-loss repair, and Indian Institute of Technology Hyderabad described lung-matrix bioinks made using osmotic decellularization. In August 2026, BioGipuzkoa Health Research Institute and the University of the Basque Country compared the composition of dECM and dECM-based inks. Together, these studies address architecture, printability and retained biological components.
What are the main approaches in decellularized tissue matrix and how do they differ?
The listed approaches are detergent-based, enzymatic, physical, perfusion and non-detergent chemical processing. Detergents and chemicals can remove cells but may alter matrix components or leave residues; enzymes target cellular material but require control of digestion and carryover. Physical methods avoid relying only on chemical agents, while perfusion can distribute processing through vascularized tissue but depends on suitable anatomy.
What are the applications of decellularized tissue matrix?
Recorded applications include wound and skin repair (599 documents), orthopedic repair (296), breast reconstruction (275), cardiovascular repair (188), and organ and tubular tissue reconstruction (56). Research also applies dECM to organoid culture, bioprinted tissue models and regenerative scaffolds. These application areas reflect different material demands, from flexible coverage to mechanically supportive or tissue-specific structures.